Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.34 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.34 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6877420 | 0.90 | PTPN1 (0.37) | PTPN1TSHRTP53TRPM8LGALS9 | |
| SCHEMBL6102299 | 0.90 | PTPN1 (0.37) | PTPN1TSHRTP53TRPM8LGALS9 | |
| SCHEMBL6099581 | 0.88 | PTPN1 (0.36) | PTPN1TSHRTP53LGALS9LGALS1 | |
| SCHEMBL6100682 | 0.84 | PTPN1 (0.37) | PTPN1TSHRTP53LGALS9LGALS1 | |
| SCHEMBL6099579 | 0.84 | PTPN1 (0.37) | PTPN1TSHRTP53LGALS9LGALS1 | |
| SCHEMBL22742954 | 0.83 | LMNA (0.38) | PTPN1TSHRTP53LGALS9LGALS1 | |
| SCHEMBL31472992 | 0.83 | LMNA (0.38) | PTPN1TSHRTP53LGALS9LGALS1 | |
| SCHEMBL6098797 | 0.83 | LMNA (0.38) | PTPN1TSHRTP53LGALS9LGALS1 | |
| SCHEMBL882327 | 0.83 | LMNA (0.38) | PTPN1TSHRTP53LGALS9LGALS1 | |
| SCHEMBL13134673 | 0.83 | LMNA (0.38) | PTPN1TSHRTP53LGALS9LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081449-B2 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | VALEANT RESEARCH & DEVELOPMENT (US) | 2006-07-25 | — | — | US | disclosed |
| US-6831069-B2 | Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis | RIBAPHARM INC. | 2004-12-14 | — | — | US | disclosed |
| EP-1303282-A4 | PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES | RIBAPHARM INC (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1212326-A4 | PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS | ICN PHARMACEUTICALS (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20030144502-A1 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | MDRNA RESEARCH, INC. | 2003-07-31 | — | — | US | disclosed |
| EP-1303282-A1 | PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES | Ribapharm, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1212326-A1 | PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS | ICN Pharmaceuticals, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | CEQUENT PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002003997-A1 | PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES | RIBAPHARM INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001027114-A1 | PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS | ICN PHARMACEUTICALS, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035077-A1 | Pyrrolo[2,3-d]pyrimidine nucleoside analogs | TYMP, DPYD, TYMS | PTPN1 1686/4885TSHR 3814/4885TP53 183/4885 |
| US-20030144502-A1 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | DPYD, TYMP, PNPO | PTPN1 1383/4885TSHR 1518/4885TP53 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.